bymuratdeniz
- Arvinas (NASDAQ:ARVN) announced that the company and its partner, Pfizer (NYSE:PFE), decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant.
- Accordingly, the VERITAC-2 monotherapy clinical trial, designed to test the protein degrader in patients with metastatic breast cancer, is expected to be completed in January, a delayed timeline from the companies’ previous projection for November 2024.
- The duo has made the decision based on the current trial status, including data on enrollments and blinded event rates. Given the revised completion date, Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) expect to share topline data from VERITAC-2 in Q1 2025.
- With its Q3 2024 results, New Haven, Connecticut-based Arvinas (ARVN) said VERITAC-2, which has completed enrollments in Q4, is anticipated to generate topline data this year or Q1 2025.